BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback